Supplemented Low Protein Diet and Progression of CKD
Stage 4 Chronic Kidney Disease
About this trial
This is an interventional prevention trial for Stage 4 Chronic Kidney Disease focused on measuring chronic kidney disease, ketoanalogue, diabetes
Eligibility Criteria
Inclusion Criteria:
- Patients with diabetic nephropathy in stage 4 chronic kidney disease
- Patients in pre-dialysis
- Patients with signed informed consent forms.
Exclusion Criteria:
- Patients who have received Ketosteril previously
- Patients participating in other intervention studies
- Pregnant women
- Patients with background of renal transplant
- Patients with cancer, HIV, seropositive for hepatitis B or C or receiving immunosuppressors, hypercalcemia
- Intolerance of Ketosteril ingredients
- Hereditary disorders in amino acid metabolism
Sites / Locations
- Unidad de Investigación Médica en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social
- Unidad de Investigacion Medica en Enfermedades Nefrologicas, Hospital de Especialidades Centro Medico Nacional Siglo XXI
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
ketoanalogues of essential amino acids
Control
Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).